Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer

Annals of Pharmacotherapy

Volumn 42, Issue 1, 2008, Pages 91-98

  Patel, Punam H ^a,b   Kockler, Denise R ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

APC8015; Prostate cancer vaccine; Sipuleucel T

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DOCETAXEL; PLACEBO; PROVENGE; SIPULEUCEL T; UNCLASSIFIED DRUG;

ANDROGEN METABOLISM; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; CANCER IMMUNIZATION; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHILL; CITRATE TOXICITY; CLINICAL TRIAL; COLD SENSATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DENDRITIC CELL; DIZZINESS; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATURIA; HUMAN; INJECTION SITE REACTION; LIMB PAIN; MALE; METASTASIS; MYALGIA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SHOULDER PAIN; SIDE EFFECT; THORAX PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

CANCER VACCINES; CONTROLLED CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE EXTRACTS;

EID: 38049048619     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K429     Document Type: Review

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER Web site 2006 (accessed 2007 Sept 24).
3. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
4. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999;17:3167-72.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
7. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1998;32:410-24.
8. Petrylak DP, Tangen CM, Hussian MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
9. Package insert. Taxotere (docetaxel). Bridgewater, NJ: Sanofi-Aventis US LLC, December 2006.
10. CNBC Pharma's Market. Dendreon: did Provenge spark early fireworks? www.cnbc.com/id/19583094/site/14081545/page/2/. (accessed 2007 Jul 7).
11. Anonymous. Provenge in 2008 hinges on interim data. FDC reports: the Pink Sheet 2007;60:23.
12. Oliver RT, Gallagher CJ. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Cancer Surv 1995;23:191-207.
13. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-803.
14. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. Biodrugs 2003;17:131-8.
15. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997;159:3113-7.
16. Solin T, Kontturi M, Pohlmann R, Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochem Biophys Acta 1990;1048:72-7.
17. Lam KW, Li CY, Yam LT, Sun T, Lee G, Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989;15:13-21.
18. Dendreon Corporation, Cellular, Tissue and Gene Therapies Advisory Committee. Sipuleucel-T briefing document (BLA STN 1251970). Food and Drug Administration. www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf. (accessed 2007 Jul 8).
19. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
20. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82.
21. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1999;5:1738-44.
22. Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002;4:76-9.
23. Scher HI, Kelly WMK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999;91:244-51.
24. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004;60:197-204.
25. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunological therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
26. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
27. Provenge (sipuleucel-T) active cellular immunotherapy treatment of metastatic prostate cancer after failing hormone therapy. ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00065442 (accessed 2007 Jun 5).
28. Dombrowski C. Provenge survival data plagued by small study size, post hoc analysis. FDC reports: the Pink Sheet 2007;69:7-8.
29. Dombrowski C. Provenge approval would include surveillance for cerebrovascular events. FDC reports: the Pink Sheet 2007;69:9-10.
30. 2006-Focus on Specialty Pharmacy. Caremark. www.caremark.com/portal/ asset/2006_SpecialtyPharmacy.pdf (accessed 2007 Jul 2).
31. Q&A: Dendreon's vaccine for prostate cancer patients. Wall Street Journal Health Blog. http://blogs.wsj.com/health/2007/03/30/ (accessed 2007 Jun 7).